Cartesian Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Cartesian Therapeutics

08/05/2025 14:32

Cartesian Therapeutics Inc RNAC.OQ reported a quarterly adjusted loss of 68 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-10.50.  The mean expectation of seven analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from -94 cents to -55 cents per share.

Revenue fell 81.2% to $1.10 million from a year ago; analysts expected $785.71 thousand.

Cartesian Therapeutics Inc's reported EPS for the quarter was a loss of 68 cents​.

The company reported a quarterly loss of $17.71 million.

Cartesian Therapeutics Inc shares had fallen by 23.0% this quarter and lost 43.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 14.4% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cartesian Therapeutics Inc is $40.50

This summary was machine generated from LSEG data May 8 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.71
-0.68
Beat
Dec. 31 2024
-0.80
-0.59
Beat
Sep. 30 2024
-0.79
-1.13
Missed
Jun. 30 2024
-1.07
0.54
Beat